Showing 1 - 7 results of 7 for search 'Songmao Zheng', query time: 0.03s Refine Results
  1. 1
    How resilient were we in 2021? Results of a LinkedIn Survey including biomedical and pharmaceutical professionals using the Benatti Resiliency Model

    How resilient were we in 2021? Results of a LinkedIn Survey including biomedical and pharmaceutical professionals using the Benatti Resiliency Model by Songmao Zheng, Karthik Venkatakrishnan, Beth Benatti Kennedy

    Published 2022-10-01
    Get full text
    Article
  2. 2
    Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?

    Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches? by Songmao Zheng, Rodney Prell, Jennifer Sheng, Yow‐Ming Wang, Lora Hamuro

    Published 2022-09-01
    Get full text
    Article
  3. 3
    A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel disease model

    A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel d... by Songmao Zheng, Jin Niu, Brian Geist, Damien Fink, Zhenhua Xu, Honghui Zhou, Weirong Wang

    Published 2020-01-01
    Get full text
    Article
  4. 4
    The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodies

    The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodies by Michelle A. Pressly, Lambertus A. Peletier, Songmao Zheng, Vishnu D. Sharma, Yi Ting (Kayla) Lien, Weirong Wang, Honghui Zhou, Stephan Schmidt

    Published 2023-05-01
    Get full text
    Article
  5. 5
    Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A

    Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A by Songmao Zheng, Fang Shen, Brian Jones, Damien Fink, Brian Geist, Ivo Nnane, Zhao Zhou, Jeff Hall, Ravi Malaviya, Tatiana Ort, Weirong Wang

    Published 2020-01-01
    Get full text
    Article
  6. 6
    A long‐acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model

    A long‐acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model by Songmao Zheng, David Polidori, Yuanping Wang, Brian Geist, Xiefan Lin‐Schmidt, Jennifer L. Furman, Serena Nelson, Andrea R. Nawrocki, Simon A. Hinke

    Published 2023-08-01
    Get full text
    Article
  7. 7
    847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies informed by QSP modeling

    847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies i... by Xin Wang, Yan Li, Meng Sun, Jiping Zha, Songmao Zheng, Guizhong Liu, Peter Luo, John J Skinner, Kristine She, Jiangchun Xu, Felix Du

    Published 2023-11-01
    Article

Search Tools: